New study aims to improve First-Line treatment for rare lymphoma
NCT ID NCT07492407
First seen Mar 28, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This study looks at how well three different antibody-based drug combinations work as the first treatment for people with a rare type of blood cancer called marginal zone lymphoma (MZL). About 131 adults who have not yet been treated will receive one of three regimens based on their risk level. The goal is to see which treatment leads to the highest rate of complete remission and helps patients live longer without the cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MZL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.